Final-Program-ATS-2023-AP.vp

SUNDAY • MAY 21

109

2:15 Session Introduction

Chairing: G. Mutlu, MD, ATSF, Chicago, IL D. Kamp, MD, Chicago, IL A. Mora, MD, Columbus, OH 2:15

L.M. Schnapp, MD, ATSF, Madison, WI 2:30 Every Mile Changes You: A Patient's Perspective K. O'Grady, Patient Speaker, Hudson, MA 2:45 The Role of Physical Conditioning in Respiratory Health D.M. Mannino, MD, Lexington, KY 3:00 Pulmonary Rehab to Support Physical Conditioning C.L. Rochester, MD, New Haven, CT 3:15 Monitoring and Tracking Physical Activity: The Role of Wearable Tech A. Chesnutt, MD, Cupertino, CA 3:30 Exercise for Chronic Lung Conditions: What is the Evidence? M.B. Brown, PT, PhD, Seattle, WA

Air Pollution, Oxidative Stress, and Cardiopulmonary Diseases: A Life Course Epidemiologic Perspective G. Thurston, DSc, New York, NY Environmental Toxins and Macrophages in Progression of Chronic Lung Disease J. Larson-Casey, PhD, Birmingham, AL Role of Innate Immune System in Environmental Lung Diseases R. Tighe, MD, ATSF, Durham, NC Understanding the Molecular Mechanisms of How Air Pollution Increases Susceptibility to Pulmonary Infections K. Gowdy, BS, MS, PhD, Columbus, OH

2:45

3:00

3:20

3:40

Questions and Answers

CLINICAL • TRANSLATIONAL SCIENTIFIC SYMPOSIUM

BASIC • BEHAVIORAL • CLINICAL SCIENTIFIC SYMPOSIUM CME Credits Available: 1.5

CME Credits Available: 1.5 MOC Points Available: 1.5

A87 NEW TREATMENT APPROACHES FOR BRONCHIECTASIS Assemblies on Pulmonary Infections and Tuberculosis; Allergy, Immunology and Inflammation; Clinical Problems 2:15 PM - 3:45 PM Walter E. Washington Convention Center Hall E (Level 2) Target Audience Clinicians and scientists engaged in clinical care and research for bronchiectasis and related conditions Objectives At the conclusion of this session, the participant will be able to: • describe new findings about the epidemiology and unmet need in patients with bronchiectasis • improve the treatment of bronchiectasis patients by better applying the evidence for long term inhaled and oral antibiotics in clinical practice • improve the treatment of bronchiectasis patients by better applying the evidence for mucus clearance treatments including airway clearance/physiotherapy and mucus targeting treatments This symposium will review the emerging evidence in the field of bronchiectasis including new data from randomized controlled trials of inhaled antibiotics, cutting edge science around endotyping, and the application of personalized medicine as well as evidence for emerging therapies targeting inflammation. Chairing: S.H. Kasperbauer, MD, Denver, CO A.E. O’Donnell, MD, WASHINGTON, DC

A86

PHYSICAL FITNESS AND LUNG HEALTH

ATS Public Advisory Roundtable 2:15 PM - 3:45 PM Walter E. Washington Convention Center Room 204 A-C (Level 2) Target Audience Providers of lung health and allied services Objectives At the conclusion of this session, the participant will be able to: • Describe current ‘state of the art’ evidence supporting the role of physical activity in maintaining lung health • Improve the quality of life/health status of patients by assessing technologies that may encourage patient engagement in physical fitness initiatives. • Describe new findings related to the role of pulmonary rehabilitation in preserving lung function and improving quality of life for individuals with lung disease This session will focus on the critical role of physical activity and conditioning in supporting respiratory health and improving patient quality of life. It will explore the current science on exercise and cardiorespiratory health, technologies to engage patients in physical activity, and the critical role of pulmonary rehabilitation in preserving respiratory health. Chairing: M. Manion, BS, Minneapolis, MN L.M. Schnapp, MD, ATSF, Madison, WI

ATS 2023 • Washington, DC